Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.
Ad hoc announcement pursuant to Art. 53 LR
NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...
About Shriners Hospitals for Children Canada Established in Montreal in 1925, Shriners Hospitals for Children Canada is a bilingual, short-term, acute care hospital, providing ultra-specialized orthopaedic care to children from across Canada and around the world. The mission of the hospital is to provide treatment and rehabilitation to infants, children and young adults with orthopaedic and neuromuscular problems such as scoliosis, osteogenesis imperfecta (brittle bone disease), clubfeet, hip dysplasia, leg length discrepancies and cerebral palsy, among others. The hospital is committed to excellence and innovation in clinical practice, research and education. Affiliated with McGill University, the hospital provides clinical experience and teaching for residents and allied professionals within its outstanding new facility on the Glen site. The hospital is present in communities across Canada, thanks to telemedicine, outreach clinics and satellite clinics.
Organization to Participate in 12 National Events as Part of Innovative Health Education Initiative
WASHINGTON, July 24, 2025 /PRNewswire/ -- LUNGevity Foundation, the nation's leading...
NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...
NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...
EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 8, 2025, the compensation committee of the Company’s board of directors granted one new non-executive employee 4,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.
Las Vegas, NV, July 03, 2025 (GLOBE NEWSWIRE) -- Area 52, a vanguard in cannabinoid science and botanical engineering, today announced the debut of its 2025 THCA Snow Caps collection, a groundbreaking line of premium hemp flower completely enveloped in pure THCA diamonds. Engineered to “Alienize Your Mind,” these crystalline-coated buds represent a new frontier in potency and sensory experience for the discerning cannabis connoisseur.
Munich, Germany – July 2, 2025 -- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that it has received Euro 2.3 million funding under the European Innovation Council (EIC) Accelerator program to advance its digital twin platform technology. In addition, the EIC fund will invest up to €10 million in future equity financing rounds raised by Ebenbuild. The funding will support the market launch of Twinhale, the first in silico trial software built for pulmonary drug delivery. The investment also underpins Ebenbuild’s broader platform strategy to transform respiratory care through personalized lung simulation – from drug development to mechanical ventilation optimization in critical care.